Sam Ropp - 15 Mar 2024 Form 4 Insider Report for Singular Genomics Systems, Inc.

Role
Chief Commercial Officer
Signature
/s/ Dalen Meeter, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Mar 2024
Net transactions value
$0
Form type
4
Filing time
19 Mar 2024, 17:49:00 UTC
Previous filing
13 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OMIC Common Stock Options Exercise +4,187 +33% 16,750 15 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OMIC Restricted Stock Units Options Exercise -4,187 -7.7% 50,250 15 Mar 2024 Common Stock 4,187 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sam Ropp is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents shares of Common Stock issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3 The RSUs vest in 16 equal quarterly installments measured from March 15, 2023.